|  |  |
| --- | --- |
| **Table 1: Demographics of patients meeting inclusion criteria (n=41)** | |
| Characteristic | n (%) |
| Male | 20 (49%) |
| Female | 21 (51%) |
| Sickle cell disease type |  |
| HbSS | 39 (95%) |
| HbSC | 1 (2.5%) |
| HbSB0 | 1 (2.5%) |
| Current age, median, (IQR) | 6 (4,10) |
| Distribution by age |  |
| 0-4 | 15 (36.5%) |
| 5-10 | 18 (43.9%) |
| 11-15 | 6 (14.6%) |
| 16-24 | 2 (4.9%) |
| Age at LHU initiation, median, (IQR) | 2 (0.75, 5.5) |
| Distribution by age | 0.75-21 |
| 0-4 y | 27 (65.9%) |
| 5-10 y | 12 (29.3%) |
| 11-15 y | 1 (2.4%) |
| 16-21 y | 1 (2.4%) |
| LHU exposure |  |
| Prior exposure | 14 (34%) |
| Distribution by age at start of LHU |  |
| 0-4 y | 4 (28.5%) |
| 5-10 y | 8 (57.1%) |
| 11-15 y | 1 (7.1%) |
| 16-21 y | 1 (7.1%) |
| No prior exposure at start of LHU | 27 (66%) |
| Distribution by age at start of LHU |  |
| 0-4 y | 23 (85.2%) |
| 5-10 y | 4 (14.8%) |
| Maximum liquid hydroxyurea dose tolerated (mg/kg/day) median, (IQR) | 22 (20, 28.5) |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 2: Comparison of pre-and post-LHU initiation laboratory values** | | | | | | | |
| Laboratory Values | N | Pre  (mean±SD) | Post  (mean+/-SD) | Difference in means | Percent Difference | 95% CI for the difference of means | P-value |
| Height percentile | 40 | 59.8±28.6 | 61.4±28.5 | 1.6±17.5 | 2.7% | -4.0 to 7.2 | 0.57 |
| Weight percentile | 40 | 44.4±27.8 | 45.6±30.8 | 1.2±11.6 | 2.7% | -2.5 to 4.9 | 0.52 |
| Height (m) | 41 | 0.92±0.33 | 1.0±0.32 | 0.08±0.07 | 8.7% | 0.06 to 0.10 | <0.0001 |
| Weight (kg) | 41 | 15.97±10.2 | 18.4±11.4 | 2.4±1.7 | 15.0% | 1.9 to 2.9 | <0.0001 |
| Hemoglobin (g/dL) | 39 | 8.7±1.3 | 9.0±1.3 | 0.34±0.91 | 3.9% | 0.04 to 0.63 | 0.02 |
| Fetal Hemoglobin percentage (%) | 30 | 19.5±11.1 | 20.8±9.9 | 1.34±6.4 | 6.8% | -1.04 to 3.7 | 0.26 |
| Mean Corpuscular Volume (Fl) | 41 | 80.2±10.5 | 83.3±10.9 | 3.2±7.1 | 3.9% | 0.92 to 5.4 | 0.007 |
| Absolute Neutrophil Count (K/µL) | 39 | 4.0±2.3 | 3.4±1.9 | -0.62±2.9 | -15.5% | -1.6 to 0.32 | 0.18 |
| Total bilirubin (g/dL) | 35 | 1.6±0.92 | 1.8±1.2 | 0.14±0.62 | 8.8% | -0.7 to 0.35 | 0.19 |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 3: Comparison of pre-and post-LHU initiation healthcare utilization among the 41 patients** | | | | | | | |
| Healthcare Measure | Pre  (mean±SD) | Post  (mean±SD) | Difference in means | Percent Difference | 95% CI for the difference of means | P-value |
| Hospitalizations | 0.76±1.11 | 0.37±0.66 | -0.39±0.95 | -51.3% | -0.69 to -0.09 | 0.01 |
| ED visits | 1.44±1.55 | 1.00±1.16 | -0.43±1.43 | -29.9% | -0.89 to 0.01 | 0.06 |
| Outpatient visits | 3.90±2.02 | 4.12±2.10 | 0.22±2.16 | 5.6% | -0.46 to 0.90 | 0.52 |
| ACS | 0.22±0.48 | 0.02±0.16 | -0.19±0.51 | -86.4% | -0.36 to -0.03 | 0.02 |
| VOE | 0.51±1.24 | 0.24±0.62 | -0.27±0.97 | -53.0% | -0.58 to 0.04 | 0.09 |